International alternative asset fund management group Bridgepoint Development Capital has acquired Prescient Healthcare Group, a Baird Capital portfolio company.
Following the transaction, Baird Capital will continue to hold a minority interest in Prescient. The terms of the transaction were undisclosed.
Prescient provides pharmaceutical intelligence, insights and product strategy and is headquartered in London with offices in the US, India and China. It partners with many multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharma organisations.
Baird Capital originally invested in Prescient in 2017 and has helped the company build out its data-driven technology platform, which now provides real-time, dynamic data and insights, alongside strategic advice to the global life sciences industry.
Andrew Ferguson, partner with Baird Capital, said: “We invested in Prescient because we saw an opportunity to leverage our global resources to help an outstanding business grow even quicker and we are very pleased to have supported Prescient’s development and success over the past few years. We look forward to continuing our relationship as a minority shareholder, and we believe Prescient will continue to thrive in partnership with Bridgepoint.”
Jamie Denison-Pender, chief executive of Prescient Healthcare Group, added: “It’s been a pleasure working with Baird Capital, and I am delighted that they will continue as an investor in Prescient. We are proud of the way we worked to build out our capabilities over the past few years, particularly in India and the US, and we are well-positioned and excited for our next phase of growth.”
Baird Capital was advised by Alantra Corporate Finance and Edgemont Partners (financial) and Squires Patton Boggs (legal).
Date published: January 21, 2021